Development of proprietary bacteriophage Qbeta as a vaccine carrier platform for anti-salmonella vaccine

项目总结 疫苗拯救了数百万人的生命。然而，有许多疾病是疫苗无法预防的。 然而，随着当前世界上的新冠肺炎大流行痛苦地提醒人们需要 针对新出现疾病的疫苗。随着人们对疫苗安全性的日益重视，下一代疫苗 设计越来越多地关注亚单位抗原。因为亚基表位往往较低 免疫原性，免疫原性载体对于将所需的抗原传递到免疫系统和 增强免疫反应。然而，经过验证的可用运营商很少 临床研究。在这个SBIR第一阶段项目中，IASO治疗公司将专注于开发一种专有的 噬菌体突变体Qβ(MQβ)病毒样颗粒作为结合疫苗的平台技术。在目标1中， 将为MQβ的表达、纯化和长期保存建立可靠的协议。此外，头部 将进行头部比较，以证明MQβ可以诱导出更高水平的抗体 到目前的基准航空公司。在Aim 2中，将应用功能强大的MQβ平台来传递沙门氏菌 相关多糖作为多种常见致病沙门氏菌的潜在疫苗。这个 疫苗将得到优化，以加强对沙门氏菌感染的保护。在成功开发后，这一点 该项目将建立MQβ作为疫苗开发的有吸引力的免疫原性载体，并提供重要的 抗沙门氏菌疫苗的临床前数据。

Project summary Vaccines have saved millions of lives. However, there are many diseases against which vaccines are not yet available, with the current COVID-19 pandemic in the world serving as a painful reminder of the need for vaccines against emerging diseases. With the growing emphasis on vaccine safety, next-generation vaccine designs have been increasingly focusing on subunit antigens. Because subunit epitopes tend to have lower immunogenicity, immunogenic carriers are critical to deliver the desired antigen to the immune system and to enhance the immune responses. However, there are very few carriers available that have been validated in clinical studies. In this SBIR phase I project, Iaso Therapeutics, Inc. will focus on the development of a proprietary bacteriophage mutant Qβ (mQβ) virus like particle as a platform technology for conjugate vaccines. In aim 1, robust protocols will be established for expression, purification, and long-term storage of mQβ. In addition, head to head comparison will be performed to demonstrate that mQβ can elicit higher levels of antibodies as compared to current benchmark carriers. In aim 2, the powerful mQβ platform will be applied to deliver Salmonella associated glycans as potential vaccines against multiple strains of common pathogenic Salmonella. The vaccine will be optimized to enhance protection from Salmonella infection. When successfully developed, this project will establish mQβ as an attractive immunogenic carrier for vaccine development and provide important pre-clinical data for anti-Salmonella vaccines.